This technology utilizes TaqMan quantitative reverse transcription polymerase chain reaction (qRT-PCR) to identify eight distinct fusion gene targets, including MAN2A1-FER, SLC45A2-AMACR, and others. It employs carefully optimized primer and probe sets, making it capable of detecting these targets even in compromised samples such as formalin-fixed paraffin-embedded tissues and other specimens with degraded nucleic acids. The assays have undergone rigorous development, culminating in in vivo testing to ensure effective performance in complex biological systems.
Description
The approach is differentiated by its unique focus on fusion genes that have not been previously addressed with similar analytical methods. Its optimization for challenging sample types fills a critical gap in molecular biology diagnostics, enabling sensitive and reliable quantification where traditional techniques may fail. Additionally, the progression to in vivo validation and the commercial interest from multiple companies underscore its potential impact in clinical diagnostics and research, offering a robust platform for future precision medicine applications.
Applications
- Fusion gene diagnostics
- Molecular pathology screening
- Oncology companion diagnostics
- Personalized medicine assays
- Biomarker assay development
Advantages
- Highly sensitive and specific detection of eight fusion genes, providing accurate quantification.
- Optimized for challenging sample types like FFPE tissues and degraded nucleic acids.
- Validated in vivo, ensuring reliability in complex biological systems.
- First assays developed for these fusion genes, filling an unmet need in molecular diagnostics.
- Attracts commercial interest with potential clinical applications in diagnostics and monitoring.
IP Status
Research Tool
